CN110536699A - 被动抗体依赖性细胞介导的活化 - Google Patents

被动抗体依赖性细胞介导的活化 Download PDF

Info

Publication number
CN110536699A
CN110536699A CN201880007963.0A CN201880007963A CN110536699A CN 110536699 A CN110536699 A CN 110536699A CN 201880007963 A CN201880007963 A CN 201880007963A CN 110536699 A CN110536699 A CN 110536699A
Authority
CN
China
Prior art keywords
leu
ala
pro
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880007963.0A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·卡里居里
余建华
代红胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CN110536699A publication Critical patent/CN110536699A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880007963.0A 2017-01-30 2018-01-30 被动抗体依赖性细胞介导的活化 Pending CN110536699A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452111P 2017-01-30 2017-01-30
US62/452,111 2017-01-30
PCT/US2018/016035 WO2018140974A1 (en) 2017-01-30 2018-01-30 Passive antibody dependent cell-mediated activation

Publications (1)

Publication Number Publication Date
CN110536699A true CN110536699A (zh) 2019-12-03

Family

ID=62979661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880007963.0A Pending CN110536699A (zh) 2017-01-30 2018-01-30 被动抗体依赖性细胞介导的活化

Country Status (6)

Country Link
US (1) US11459378B2 (enExample)
EP (1) EP3573640A4 (enExample)
JP (1) JP2020505418A (enExample)
CN (1) CN110536699A (enExample)
AU (1) AU2018213418A1 (enExample)
WO (1) WO2018140974A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111411079A (zh) * 2020-03-27 2020-07-14 北京时合生物科技有限公司 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
CN114621356A (zh) * 2022-05-17 2022-06-14 康希诺生物股份公司 以il18为分子佐剂的带状疱疹亚单位疫苗

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
MX2022000879A (es) * 2019-07-21 2022-05-02 Glaxosmithkline Biologicals Sa Vacuna viral terapeutica.
WO2024086400A1 (en) * 2022-10-17 2024-04-25 Research Institute At Nationwide Children's Hospital Macrophage polarizing oncolytic herpes simplex virus for cancer therapy
WO2024254444A1 (en) * 2023-06-09 2024-12-12 Cornell University Vaccines for human cytomegalovirus

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070036799A1 (en) * 2005-08-10 2007-02-15 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20120244578A1 (en) * 2009-11-23 2012-09-27 Amgen Inc. Monomeric antibody fc
US20130251706A1 (en) * 2010-08-20 2013-09-26 University Of Southampton Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies
US20150050278A1 (en) * 2012-03-16 2015-02-19 The United States of America, as represented by the Secretary, Dep. of Health and Human Sevices Soluble engineered monomeric fc
US20150368668A1 (en) * 2008-04-22 2015-12-24 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
CN105669838A (zh) * 2014-12-04 2016-06-15 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070036799A1 (en) * 2005-08-10 2007-02-15 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20150368668A1 (en) * 2008-04-22 2015-12-24 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US20120244578A1 (en) * 2009-11-23 2012-09-27 Amgen Inc. Monomeric antibody fc
US20130251706A1 (en) * 2010-08-20 2013-09-26 University Of Southampton Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies
US20150050278A1 (en) * 2012-03-16 2015-02-19 The United States of America, as represented by the Secretary, Dep. of Health and Human Sevices Soluble engineered monomeric fc
CN105669838A (zh) * 2014-12-04 2016-06-15 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RECTOR等: "Use of Monoclonal Antibodies for Analysis of Antibody-Dependent Immunity to Ocular Herpes Simplex Virus Type 1 Infection", 《INFECTION AND IMMUNITY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111411079A (zh) * 2020-03-27 2020-07-14 北京时合生物科技有限公司 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
CN114621356A (zh) * 2022-05-17 2022-06-14 康希诺生物股份公司 以il18为分子佐剂的带状疱疹亚单位疫苗

Also Published As

Publication number Publication date
EP3573640A1 (en) 2019-12-04
US20200040064A1 (en) 2020-02-06
JP2020505418A (ja) 2020-02-20
WO2018140974A1 (en) 2018-08-02
AU2018213418A1 (en) 2019-06-20
EP3573640A4 (en) 2021-04-28
US11459378B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
US11459378B2 (en) Passive antibody dependent cell-mediated activation
JP6895374B2 (ja) 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
JP2021531737A (ja) ウイルス療法を増強するための細胞ベースの媒体
US20230357793A1 (en) Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
JP2020529422A (ja) 急性骨髄性白血病を治療するためのｆｌｔ３ ｃａｒ−ｔ細胞及びｆｌｔ３阻害剤の使用
KR102950505B1 (ko) M2 결함성 폭스바이러스
JP2022502074A (ja) 改変された腫瘍溶解性ウイルス、組成物、およびその使用
US20250257135A1 (en) Novel antibodies and nucleotide sequences, and uses thereof
AU2019244150B2 (en) Swelling-suppressive oncolytic virus
CN114375331B (zh) 用于脑肿瘤治疗的溶瘤性i型单纯疱疹病毒
WO2022217048A1 (en) Oncolytic viruses expressing anti-ror1/anti-cd3 bispecific antibodies
US20240374719A1 (en) Novel combinations of antibodies and uses thereof
US20040013672A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
KR20220092905A (ko) 입양 면역요법
KR20250044313A (ko) Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물
RU2819245C2 (ru) M2-дефектный поксвирус
CN118176016A (zh) 抗体的新型组合及其用途
Froechlich Dissecting the STING-dependent molecular mechanisms in a preclinical model of combined treatment with tumour-targeted Herpes simplex virus and immune checkpoint blockade
Nuévalos Guaita Characterization of the immune response against Cytomegalovirus for the isolation of monoclonal antibodies. New strategies for the prevention and treatment of CMV infection
WO2025185740A1 (zh) 一种修饰的溶瘤病毒及其组合物
CN101300274A (zh) 免疫调节组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191203